Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026799 | 0.83 | NPSR1 (0.66) | S100A4NPSR1PTPRCCYP1B1MAPT | |
| SCHEMBL30441823 | 0.78 | NPSR1 (0.47) | S100A4NPSR1PTPRCCYP1B1MAPT | |
| SCHEMBL14700627 | 0.69 | ALDH1A1 (0.47) | S100A4NPSR1PTPRCCYP1B1MAPT | |
| SCHEMBL1890003 | 0.66 | TYMS (0.64) | NPSR1CYP1B1MAPTKMT2AMAPK1 | |
| SCHEMBL28588478 | 0.65 | TDP1 (0.45) | NPSR1MAPTALDH1A1KMT2AGABRA1 | |
| SCHEMBL5749227 | 0.65 | NPSR1 (1.00) | NPSR1CYP1B1MAPTMCL1CES1 | |
| SCHEMBL31156926 | 0.65 | NPSR1 (1.00) | NPSR1CYP1B1MAPTMCL1CES1 | |
| SCHEMBL29594014 | 0.65 | S100A4 (0.80) | S100A4PTPRCMCL1CES1BCL2 | |
| SCHEMBL29514452 | 0.65 | S100A4 (1.00) | S100A4PTPRCMCL1CES1BCL2 | |
| SCHEMBL1290049 | 0.65 | S100A4 (1.00) | S100A4PTPRCMCL1CES1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | CRYSOPTIX KK | 2011-03-17 | — | — | US | disclosed |
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | CRYSOPTIX KK | 2011-03-17 | — | — | US | disclosed |
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | CRYSOPTIX KK | 2011-03-17 | — | — | US | disclosed |
| EP-2260036-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009109782-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109782-A2 | POLYCYCLIC ORGANIC COMPOUNDS, RETARDATION LAYER AND COMPENSATION PANEL ON THEIR BASE | CRYSOPTIX K.K. (JP) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064892-A1 | Polycyclic Organic Compounds, Retardation Layer and Compensation Panel on Their Base | MCM3, CCNA2, CCNB2 | S100A4 376/4885NPSR1 4119/4885PTPRC 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.